Cigna Group (NYSE:CI – Get Free Report) and INVO Fertility (NASDAQ:IVF – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Cigna Group and INVO Fertility, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cigna Group | 0 | 8 | 14 | 0 | 2.64 |
| INVO Fertility | 1 | 0 | 0 | 1 | 2.50 |
Cigna Group currently has a consensus price target of $335.70, suggesting a potential upside of 14.32%. INVO Fertility has a consensus price target of $320.00, suggesting a potential upside of 14,853.27%. Given INVO Fertility’s higher possible upside, analysts plainly believe INVO Fertility is more favorable than Cigna Group.
Institutional & Insider Ownership
87.0% of Cigna Group shares are owned by institutional investors. Comparatively, 12.0% of INVO Fertility shares are owned by institutional investors. 0.6% of Cigna Group shares are owned by company insiders. Comparatively, 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Cigna Group has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.
Profitability
This table compares Cigna Group and INVO Fertility’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cigna Group | 2.09% | 19.57% | 5.35% |
| INVO Fertility | -116.29% | -85.54% | -31.05% |
Valuation & Earnings
This table compares Cigna Group and INVO Fertility”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cigna Group | $285.98 billion | 0.27 | $5.96 billion | $22.66 | 12.96 |
| INVO Fertility | $7.53 million | 0.18 | -$25.13 million | ($33.83) | -0.06 |
Cigna Group has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than Cigna Group, indicating that it is currently the more affordable of the two stocks.
Summary
Cigna Group beats INVO Fertility on 12 of the 15 factors compared between the two stocks.
About Cigna Group
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
About INVO Fertility
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
Receive News & Ratings for Cigna Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Group and related companies with MarketBeat.com's FREE daily email newsletter.
